Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celyad OncologyCLYYF -20.00%28 Equity-to-Asset is 0.57 as of Dec. 2025, which is 8% above its 10-year median of 0.53. GuruFocus rates CLYYF with a GF Score™ of 28/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Celyad Oncology ranks worse than 61.58% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Celyad Oncology's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $2.85 Mil. Celyad Oncology's Total Assets for the quarter that ended in Dec. 2025 was $5.03 Mil.
Therefore, Celyad Oncology's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.57.
The historical rank and industry rank for Celyad Oncology's Equity-to-Asset or its related term are showing as below:
CLYYF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.05 Med: 0.53 Max: 0.66
Current: 0.57
During the past 13 years, the highest Equity to Asset Ratio of Celyad Oncology was 0.66. The lowest was 0.05. And the median was 0.53.
CLYYF's Equity-to-Asset is ranked worse than 61.58% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs CLYYF: 0.57
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Celyad Oncology Equity-to-Asset Related Terms
Celyad Oncology Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLYYF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Celyad Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Celyad Oncology's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (CLYYF) has a Equity-to-Asset of 0.57 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Celyad Oncology and its competitors. This is near median its historical median of 0.53. Over the past decade, Celyad Oncology's Equity-to-Asset has ranged from 0.05 to 0.66. According to the industry distribution chart, Celyad Oncology ranks #872 out of 1416 companies in the Biotechnology industry, placing it in the top 61.6%.
Is Celyad Oncology's Equity-to-Asset too high?
Celyad Oncology's current Equity-to-Asset of 0.57 is near median its 10-year median of 0.53. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.66. The Biotechnology industry median Equity-to-Asset is 0.68. Celyad Oncology's value of 0.57 is 16.2% below this industry median. Based on the distribution chart, Celyad Oncology ranks #872 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #872 out of 1416 companies for Equity-to-Asset. This places Celyad Oncology in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Celyad Oncology's value of 0.57 is 16.2% below this benchmark. Historically, Celyad Oncology's own Equity-to-Asset has ranged from 0.05 to 0.66 over the past decade. While the company's 10-year median is 0.53 vs. the industry median of 0.68, Celyad Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celyad Oncology's current Equity-to-Asset of 0.57 is 16.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Celyad Oncology and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celyad Oncology's current Equity-to-Asset is 0.57, which is near median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.20 — trading 33.3% above its estimated fair value. The current Equity-to-Asset is 0.57, which is near median its 10-year median of 0.53 and 16.2% below the Biotechnology industry median of 0.68. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Equity-to-Asset is 0.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued.
The current stock price of $0.20 is trading 33.3% above its estimated GF Value™ of $0.15.
GuruFocus considers Celyad Oncology to be Significantly Overvalued.
Key valuation signals for CLYYF:
Equity-to-Asset: 0.57 (near median its 10-year median of 0.53)
GF Value™: $0.15 vs. price of $0.20 (33.3% above fair value)
Industry Position: 16.2% below the Biotechnology median (#872 of 1416)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
